In the original article, there was a nonconsequential error in Figure 1 as published. A file concatenation error occurred within the FACS analysis software that implicated the scatter dot-plots shown in Figure 1C. The corrected Figure 1 appears below.
Figure 1
The associated corrected values that appear in the text of the Results under the subheading “PEMF and Doxorubicin Treatments Act Synergistically to Impair Breast Cancer Tumor Growth In Vivo”, paragraph one, should read “Moreover, the incidence of apoptotic cells increased by +0.55%, +10.2%, and +18% in tumors isolated from control, PEMF-exposed and DOX-treated mice, respectively (Figures 1C, D)”.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
breast cancer, PEMFs, EMT, patient-derived xenograft, chorioallantoic membrane, doxorubicin, TRPC1, chemotherapy
Citation
Tai YK, Chan KKW, Fong CHH, Ramanan S, Yap JLY, Yin JN, Yip YS, Tan WR, Koh APF, Tan NS, Chan CW, Huang RYJ, Li JZ, Fröhlich J and Franco-Obregón A (2022) Corrigendum: Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach. Front. Oncol. 12:892408. doi: 10.3389/fonc.2022.892408
Received
09 March 2022
Accepted
31 March 2022
Published
20 April 2022
Volume
12 - 2022
Edited and reviewed by
Tarik Smani, Sevilla University, Spain
Updates
Copyright
© 2022 Tai, Chan, Fong, Ramanan, Yap, Yin, Yip, Tan, Koh, Tan, Chan, Huang, Li, Fröhlich and Franco-Obregón.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Alfredo Franco-Obregón, suraf@nus.edu.sg
This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.